Ecleralimab
Ecleralimab (CSJ-117; NVP-CSJ117) is a Fab-IgG1-λ2 antibody targeting the thymic stromal lymphopoietin (TSLP) . Ecleralimab significantly attenuates allergen-induced airway responses and inflammation. Ecleralimab can be used for the study of inhaled asthma[1].
Product Specifications
CAS Number
2415207-91-7
Product Name Alternative
CSJ-117; NVP-CSJ117
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ecleralimab.html
Purity
97.35
Solubility
10 mM in DMSO
Smiles
[Ecleralimab]
Molecular Weight
(46.62 kDa)
References & Citations
[1]Gauvreau GM, et al.Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J. 2023 Mar 9;61 (3) :2201193.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Rabbit Polyclonal Paralemmin Antibody [PE]](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
